Those arent studies those are individual physicians opinions. Dr Graveline was on to something but all he did was point to the fact that some statins still work where it matters. Too bad is reserch is from back before 2006 so he is a little dated to say the least..
This is a study
The study, called Jupiter, found that Crestor reduced the risk of heart-related death, heart attacks and other serious cardiac problems by 44% compared with those given placebos. The 17,802 participants were entering prime heart-attack ages -- over 50 years for men and over 60 for women -- but none had evidence of serious heart disease or cholesterol levels high enough to call for treatment under current guidelines.
All participants did have elevated levels in their blood of C-reactive protein, or CRP, an inflammatory marker that in previous studies has been shown to identify patients at heart risk independent of their cholesterol levels. Half of heart attacks occur in people with normal cholesterol. As a result, some experts say the study supports broad use of a high-sensitivity CRP test to find people who may be falsely assured by low cholesterol levels that they are protected from trouble and determine if they might be candidates for treatment. High-sensitivity CRP tests are available just like cholesterol lab tests, and are already covered by insurance in many cases.
"This takes prevention to a new level," said Douglas Weaver, head of cardiology at Henry Ford Hospital, Detroit, who wasn't involved with the Jupiter study. "It defines a new population" of patients at risk.
Jupiter is the talk of the heart meeting in New Orleans, which is expected to draw more than 25,000 cardiologists and other attendees involved in battling cardiovascular disease. Doctors and investors have been awaiting the results since last March, when the trial was halted after an interim check found overwhelming benefit for the drug. That was after patients had been followed for an average of just 1.9 years, two years earlier than planned. (It would be unethical to continue the trial when you could be harming patients knowingly by withholding medication)
The findings will stir new debate in a field already divided over the role of high-sensitivity CRP testing in clinical practice. They are certain to figure in deliberations of U.S. cholesterol experts who plan a major update of prevention and cholesterol guidelines next year. Jupiter researchers estimate that six million people in the U.S. meet the criteria of those participating in the study and thus might benefit from statin therapy; some analysts put the number above 10 million.
The study comes after the uproar early this year when the cholesterol drug Vytorin failed to show a benefit in a trial involving a controversial surrogate for heart risk. The episode involving the Merck & Co. and Schering-Plough Corp. drug triggered skepticism about the value of statin therapy and the benefit of lowering LDL, or bad cholesterol. Researchers said the new data should dispel those concerns.
"This is very reassuring for statins as a class and for the public at large," said Paul Ridker, a cardiologist at Harvard Medical School and Brigham and Women's Hospital who led the Jupiter study. The drugs "are highly effective at doing what really matters," preventing serious heart-related events.
In the study, which randomized patients to 20 milligrams of Crestor or placebo, LDL cholesterol among patients taking the drug plunged 50% to an average of 55, the lowest achieved to date in a major statin study. CRP fell 37% and wasn't associated with how much LDL was reduced. Deaths from any cause were reduced by 20%, the first time that has been shown in people without diagnosed heart disease. Among women, the drug lowered risk of major events 46%, with a similar reduction for blacks and Hispanics. Risk of a first heart attack, stroke and the need for procedures to clear or bypass clogged arteries declined at rates from 46% to 54%.
"Those benefits are approximately twice as large as what doctors expect when you use statins in patients with [high cholesterol]," Dr. Ridker said. "And they didn't have [high cholesterol]. What they had was high CRP."
What I am trying to say is you dont know what you are talking about.. If The OP has markers for heart disease and he as he says is doing carido and lifting and also has familial history of heart disease then he should be doing what counts. I do like the idea of taking anti inflammatories like fish oils etc but they have yet to be proven as effective. Point is if its me and mine I would try diet and exercise but if unable, until the medical community comes up with new guidlines for treatments and markers, I will stick with what has been shown to provide the best results.. Im taking the advice from the American College of Cardiology not DR so n so who feels one way or the other about how to treat.